Miami Cancer Institute shares their unique approach to helping patients with cancer understand why biosimilars may be their best—and most cost-effective—option for treatment.
Find the CANCER BUZZ podcast on Apple Podcasts, Spotify, or wherever you get your podcasts!
When biosimilars were first introduced in the U.S. in 2015, it was expected that they would would deliver equally effective treatment to patients as their reference products at a reduced cost for cancer programs and patients. However, it can be difficult to explain to patients that biosimilars may be their best—and most cost-effective—option.
On this episode of CANCER BUZZ, Miami Cancer Institute shares their unique approach to patient understanding: a biosimilars education course that explains what biosimilars are, how they are used, the testing process they go through, and how their use can affect insurance approvals and out-of-pocket expenses.
Guests:
Related Content:
The views and opinions expressed herein are those of the author(s)/faculty member(s) and do not reflect the official policy or position of their employer(s) or the Association of Cancer Care Centers.
July 8, 2026
June 30, 2026
At the 2026 ASCO Annual Meeting, the Louisiana Oncology Society received the ASCO Jeffrey C Ward Affiliate Advocacy Award for advancing critical advocacy priorities that have translated into meaningful legislative victories. The Iowa Oncology Society and Washington State Medical Oncology Society were also recognized for their advocacy efforts in 2025 at the meeting, receiving second place awards.
